{"id":"W3212498888","doi":"10.1182/blood-2021-144730","title":"Initial Safety and Efficacy Results from the Phase II, Multicenter, Open-Label Solace-Kids Trial of Crizanlizumab in Adolescents with Sickle Cell Disease (SCD)","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"SickKids Foundation; University of Toronto","funders":"","keywords":"Medicine; Dosing; Pharmacokinetics; Clinical trial; Placebo; Internal medicine; Clinical endpoint; Pharmacodynamics; Adverse effect; Gastroenterology; Pharmacology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002513811,0.0006981875,0.00116459,0.000166824,0.0004290663,0.0008843109,0.0005164561,0.0008143309,0.004223704],"category_scores_gemma":[0.002116261,0.00026249,0.00103261,0.0002322283,0.0006457856,0.0007357888,0.0003361463,0.002569235,0.0006354071],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007800563,"about_ca_system_score_gemma":0.001070837,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004979,"about_ca_topic_score_gemma":0.001635183,"domain_scores_codex":[0.9992611,0.0003691884,0.00005777573,0.0001317285,0.00009399711,0.00008628432],"domain_scores_gemma":[0.9982535,0.000454455,0.0003765293,0.0001155631,0.0001795054,0.0006204249],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8197755,0.01500141,0.03356724,0.001496811,0.002584438,0.0004950858,0.0005113721,0.001695628,0.0214064,0.0006118504,0.01577131,0.087083],"study_design_scores_gemma":[0.6703435,0.2505428,0.05740637,0.000235946,0.001854062,0.001152074,0.000268837,0.001537955,0.007218265,0.000563992,0.008816832,0.00005934011],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9839358,0.004752852,0.0004783259,0.0008464508,0.00009906054,0.001377849,0.004438449,0.00005753341,0.004013542],"genre_scores_gemma":[0.9892519,0.001212795,0.001044711,0.0008879727,0.0001289022,0.0008167786,0.005342413,0.00001882113,0.001295667],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004223704,"threshold_uncertainty_score":0.0141297,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02047883934578233,"score_gpt":0.29530869868982,"score_spread":0.2748298593440376,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}